Literature DB >> 11294935

SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.

W Jagust1, R Thisted, M D Devous, R Van Heertum, H Mayberg, K Jobst, A D Smith, N Borys.   

Abstract

OBJECTIVE: Numerous studies have suggested that temporoparietal hypoperfusion seen on brain imaging with SPECT may be useful in diagnosing AD during life. However, these studies have often been limited by lack of pathologic validation and unrepresentative samples. The authors performed this study to determine whether SPECT imaging provides diagnostically useful information in addition to that obtained from a clinical examination.
METHODS: Clinical data and SPECT images were collected prospectively, and patients were followed to autopsy. Clinical history, pathologic findings, and SPECT images were each evaluated by raters blind to other features, and clinical and SPECT diagnoses were compared with pathologic diagnoses. The study population consisted of 70 patients with dementia, followed to autopsy; 14 controls followed to autopsy; and 71 controls (no autopsy performed). The primary outcome was the likelihood of a pathologic diagnosis of AD given a positive clinical diagnosis, a positive SPECT diagnosis, and both.
RESULTS: When all participants (patients and controls) were included in the analysis, the clinical diagnosis of "probable" AD was associated with an 84% likelihood of pathologic AD. A positive SPECT scan raised the likelihood of AD to 92%, whereas a negative SPECT scan lowered the likelihood to 70%. SPECT was more useful when the clinical diagnosis was "possible" AD, with the likelihood of 67% without SPECT, 84% with a positive SPECT, and 52% with a negative SPECT. Similar results were found when only patients with dementia were included in the analysis.
CONCLUSIONS: In the evaluation of dementia, SPECT imaging can provide clinically useful information indicating the presence of AD in addition to the information that is obtained from clinical evaluation.

Entities:  

Mesh:

Year:  2001        PMID: 11294935     DOI: 10.1212/wnl.56.7.950

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

Review 1.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Imaging Alzheimer's disease.

Authors:  Scott A Small
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

3.  For: Can ROI methodology/normalised tissue activities be used instead of absolute blood flow measurements in the brain?

Authors:  Durval C Costa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07       Impact factor: 9.236

Review 4.  Dynamic single photon emission computed tomography--basic principles and cardiac applications.

Authors:  Grant T Gullberg; Bryan W Reutter; Arkadiusz Sitek; Jonathan S Maltz; Thomas F Budinger
Journal:  Phys Med Biol       Date:  2010-09-22       Impact factor: 3.609

5.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

6.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 7.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

Review 8.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Prevention of progression to dementia in the elderly: rationale and proposal for a health-promoting memory consultation (an IANA Task Force).

Authors:  S Gillette Guyonnet; G Abellan Van Kan; S Andrieu; J P Aquino; C Arbus; J P Becq; C Berr; S Bismuth; B Chamontin; T Dantoine; J F Dartigues; B Dubois; B Fraysse; T Hergueta; H Hanaire; C Jeandel; S Lagleyre; F Lala; F Nourhashemi; P J Ousset; F Portet; P Ritz; P Robert; Y Rolland; C Sanz; M Soto; J Touchon; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-10       Impact factor: 4.075

Review 10.  Current and future uses of neuroimaging for cognitively impaired patients.

Authors:  Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.